Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06624865
Recruiting Observational

Microbiota and Carcinogenesis of Small-intestine Neuroendocrine Tumors

NCT06624865 · tracked via the Priya Life Science France tracker
Sponsor
Hospices Civils de Lyon
Phase
Observational
Started
2024-11-05
Last updated
2025-04-04

Condition(s) studied

Small-intestine Neuroendocrine Tumors

Investigational drug(s) / intervention(s)

Blood and stool sampling

Blood and stool sampling: Blood and stool sampling

Study summary

The aim of the study is to investigate the impact of the microenvironment on tumorigenesis of small intestinal neuroendocrine tumors often located in the terminal ileum, without identified driver mutations.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient with one or more small-intestine neuroendocrine tumor with indication of surgery * Patient with consent for the collection, storage and reuse of data associated with his/her disease * Age ≥ 18 years at the time of inclusion * Non-objection statement obtained for participation in the study Exclusion Criteria: * Patients with poorly differentiated neuroendocrine carcinoma or NET (neuroendocrine tumors) of non-intestinal origin or mixed tumors (MiNEN) * Pregnant, parturient or breast-feeding women * Minors * Persons deprived of liberty by judicial or administrative decision * Adults under legal protection (guardianship, curatorship)

Primary outcome measure(s)

  • Composition of microbiota — At day 1 and month 3
    Determination of the composition of blood, fecal, intra- and peri-tumoral microbiota in patients undergoing surgery for small-intestine neuroendocrine tumor.

Trial sites (1)

FacilityCityRegionStatus
Edouard Herriot University Hospital Lyon France Recruiting

More Hospices Civils de Lyon trials in France

Non-invasive Personalized Transcranial Cortical Neurostimulation for Pain Relief Recruiting
Validation of the French Version of the New Mobility Score (NMS) Recruiting
Burosumab and 1-25 (OH) Vitamin D on Human Osteoblasts Recruiting
Impact of Mental Health First Aid-trained Peers on the Mental Well-being of First-year Medical Residents. Active, not recruiting
Psychological Support Interventions for Women With Endometriosis (ENDOPSY) Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06624865 on ClinicalTrials.gov ↗ ← All trials in France